Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. O'Connor CM, et al. Among authors: gheorghiade m. Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Am Heart J. 2010. PMID: 20435194 Clinical Trial.
Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. O'Connor CM, et al. Among authors: gheorghiade m. Am Heart J. 2008 Oct;156(4):662-73. doi: 10.1016/j.ahj.2008.04.030. Am Heart J. 2008. PMID: 18926148
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Pang PS, et al. Among authors: gheorghiade m. Am Heart J. 2011 Jun;161(6):1067-72. doi: 10.1016/j.ahj.2011.02.027. Am Heart J. 2011. PMID: 21641352 Clinical Trial.
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: gheorghiade m. Eur Heart J. 2011 Oct;32(20):2563-72. doi: 10.1093/eurheartj/ehr238. Epub 2011 Jul 23. Eur Heart J. 2011. PMID: 21785107 Clinical Trial.
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. Mentz RJ, et al. Among authors: gheorghiade m. J Card Fail. 2012 Jul;18(7):515-23. doi: 10.1016/j.cardfail.2012.04.010. Epub 2012 Jun 4. J Card Fail. 2012. PMID: 22748484 Clinical Trial.
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Mentz RJ, et al. Among authors: gheorghiade m. Eur J Heart Fail. 2013 Jan;15(1):61-8. doi: 10.1093/eurjhf/hfs139. Epub 2012 Sep 11. Eur J Heart Fail. 2013. PMID: 22968743 Free PMC article. Clinical Trial.
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP. Mentz RJ, et al. Among authors: gheorghiade m. Am Heart J. 2012 Dec;164(6):884-92.e2. doi: 10.1016/j.ahj.2012.09.011. Epub 2012 Oct 29. Am Heart J. 2012. PMID: 23194489 Clinical Trial.
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Ambrosy AP, et al. Among authors: gheorghiade m. Am Heart J. 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29. Am Heart J. 2013. PMID: 23351825 Clinical Trial.
719 results